TRANSGENIC ANIMALS

Abstract: A method for creating new breeds of animals which comprises: (a) obtaining a recently fertilised ovum; (b) isolating a gene sample of a characterising hormone homologous with the ovum; (c) introducing the gene sample into the male nucleous of the ovum prior to fusion with the female nucleous to form a single cell embryo; and (d) subsequently implanting the ovum into a suitably prepared female animal. Wherein in a preferred method there is used a plasmid expression vector comprising a plasmid cloning vector including a first cloned sequence of DNA encoding a non-porcine promoter region and a second cloned sequence encoding porcine growth hormone activity.

Description: TRANSGENIC ANIMALS This invention relates to animal husbandry and in particular to methods of creating new breeds of animals having desired characteristics, such as, increased weight gain, feed efficiency, milk production or disease resistance. In traditional breeding processes is has been possible to achieve animals with particular desired characteristics. However, many unwanted, as well as the desired characteristics are often obtained in such processes. Recently there has been major developments relating to the introduction of exogenous genes into the gene line of animals. In general, this is achieved by the use of both R/DNA technology (which includes isolation and characterisation of a gene) and one-cell embryo techniques, including egg collection and re-implantation. In summary the overall method involves the following steps: isolation of a pure gene sample (a fragment of DNA; collection of a recently fertilised egg; _Q - injection of a tiny portion (e.g. 10 of one cube centimetre) of the gene solution into the male nucleus (from the sperm) before it fuses with the female nucleus to form the one-cell embryo; and implanting the injected egg into a suitably prepared surrogate mother. After the offspring is born, a small portion of tissue (usually the tail) is taken and DNA is prepared therefrom which can be assessed to establish whether the gene injected at the one-cell stage has been stably incorporated into the animal's chromosomes. If so, it is transgenic. The process described above has been successfully used to accelerate growth and increase size in mice by the introduction of a gene construct incorporating exogenous genes, such as human growth hormone. However, the process has not been successful in attempts to enhance desired characteristics in farm animals. It is an object of the present invention to overcome, or at least alleviate, one or more of the difficulties and/or deficiencies related to the prior art processes. According to one aspect of the present invention there is provided a method for creating new breeds of animals which comprises: (a) obtaining a recently fertilised ovum; (b) isolating a gene sample of a characterising hormone homologous with the ovum; (c) introducing the gene sample into the male nucleus of the ovum prior to fusion with the female nucleus to form a single cell embryo; and (d) subsequently implanting the ovum into a suitably prepared female animal. The recently fertilised ovum may be of any suitable animal. Suitable animals include farm animals such as horses, cows, pigs, sheep, goats, turkeys and also marine animals such as abalone. The fertilised ovum may be obtained by any known method. The gene sample of a characterising hormone homologous with the ovum will necessarily be dependent upon the animal egg obtained. For-example, if the animal egg obtained is of a pig then the gene sample will comprise characterising pig hormones. The type of characterising hormones isolated and injected may be any desired characteristic hormones. The type of hormones isolated and injected may be dependent upon the desired characteristics of the off-spring. For example, if the off-spring is a porcine animal and the desired characteristic is accelerated growth, the gene sample may comprise porcine growth hormone. The gene sample may be isolated by any known method. According to a further aspect of the present invention there is provided a plasmid expression vector including a first cloned sequence of DNA encoding a non-porcine promoter region and a second cloned sequence of DNA having porcine growth hormone (PGH) activity. The plasmid expression vector so formed may include a complete copy of the porcine growth hormone in the coding region. Any suitable plasmid expression vector or cloning vector may be used. For example the plasmid cloning vector pUC19 (Nonander et al, 1983 Gene 26.: 101-106) has been found to be suitable. The first cloned sequence of DNA may encode a human promoter region. The human promoter region may be the human metallothioneine promoter (hMTIIA) . In a preferred form, a modified metallothioneine promoter plasmid may be used. The first cloned sequence of DNA may form an Eco Rl - Hind III insertion in the plasmid cloning vector. This insertion may be approximately 810 - 823bp in length. In a preferred embodiment it is 823bp in length. The first cloned sequence of DNA may also contain elements of the human metallothioneine promoter. The DNA sequence coding for porcine growth hormone activity may be isolated from a cDNA library formed from messenger or polyadenylated RNA. For example this may be isolated from porcine pituitary tissue. The second cloned sequence of DNA may form an Eco RI - Eco RI insertion in the plasmid expression vector. This insertion may be approximately 522 bp in length. The plasmid is a small, high copy number expression vector. The plasmid expansion vector may be plasmid pUC19 or pKT52. The plasmid according to the present invention may further include a third cloned sequence of DNA. The third cloned sequence may include the 3 ' end of the porcine growth hormone gene. The third cloned fragment may form an Sma : Bam/Sma insertion in the second cloned fragment of DNA. This insertion may be approximately 1000 bp in length. The 3' end fragment may also be modified. In one embodiment the certain regions identified as repeated sequences are deleted. For example the repeats may be deleted to leave approximately 200 base-pairs of 3" fragment as opposed to approximately lOOObp in the original sequence. The modifying of the 3" end of the porcine growth hormone DNA sample to remove repeated sequences is an additional contributing factor to stabilise chromosomal rearrangements of transgenes in the pig genome. This stabilisation may also be achieved by including introns in the porcine gene coding region. It has been found surprisingly that the inclusion of the 3 ' end fragment to the coding region may provided added stability to the read-out sequence (the messenger RNA or mRNA) from the gene. A particular plasmid of the type described above is that designated pH MPG.4, a sample of which is maintained in the culture collection of the University of Adelaide, Australia. Accordingly in a preferred aspect of the present invention, there is provided the plasmid pHMPG.4. A diagram of the pHMPG.4 construct is provided in Figure 1. In a further aspect of the present invention there is provided a method of preparing a plasmid expression vector as described above which includes - providing a suitable plasmid cloning vector, a first fragment of DNA containing a non-porcine promoter, and a second fragment of DNA coding for porcine growth hormone; inserting the first fragment of DNA into the plasmid cloning vector at a suitable site; and inserting the second fragment of DNA into the plasmid cloning vector at a suitable site. The method according to this aspect of the present invention may further include: - providing a third cloned fragment of DNA including the 3' end of the porcine growth hormone gene from the chromosomal copy of the porcine growth hormone gene. This further step may be achieved by cleaving the restricted plasmid expression vector at a restriction site for the porcine growth hormone DNA portion and cloning the third fragment of DNA into the second fragment at a suitable site. These steps are summarised in Figure 2. It will be understood that the method of preparing a plasmid so described may include the preliminary step of characterising the coding region and when relevant the 3 ' non-coding region of porcine growth hormone. This characterisation of porcine growth hormone is described below. The neucleatide sequence of the PGH genonic gene is illustrated in Figure 1. The plasmid or gene sample, for example the porcine growth sample Hind III/PvuI segment derived from the plasmid shown in Figure 1, may be introduced into the male pronucleus of an ovum of a porcine animal by any suitable method. The gene sample may be injected into the male pronucleus of the ovum. In a preferred aspect of the present invention, there is provided a method of preparing a transgenic animal including: (a) providing a recently fertilized ovum from a female of the animal; (b) preparing a plasmid expression vector containing the first and second cloned fragments of the promoter and cloning regions of the gene to be expressed, and (c) injecting the plasmid into the male pronucleus prior to fusion with the female nucleus to form a single cell embryo. A major problem encountered with the injection of the gene construct into the male pronucleus is visualisation of the pronuclei or nuclei in the ova. Nuclear structures of such animals as rabbits may be readily seen. However, pronuclei and nuclei in such animals as sheep and pigs are difficult to locate. Pronuclei and nuclei of sheep ova may be seen by fluorescent microscopy using DNA specific fluorochromosomes or by interference contrast (IC) microscopy. The combination of stain and ultraviolet light may be damaging to the ovum. Therefore interference contrast microscopy is preferred for microinjection of sheep ova. Fluorescent analysis has indicated that interference contrast microscopy is an effective method for pronuclear localisation in approximately 80% of fertilised sheep ova. A similar process may be used to visualise pronculei and nuclei of goat ova. Pig ova are opaque and no nuclear structures can be seen even with interference contrast microscopy. However, the pronuclei or nuclei of pig ova may be visible if natural pig ova is centrifuged at 15000 g for 3 min. A similar process may also be used to visualise pronuclei and nuclei of cow ova. However, centrifugation does not help visualisation of pronuclei of sheep ova. The injection of the pronucleus may be carried out under magnification and use of standard microinjection apparatus. The ova may be held by a blunt holding pipette and the zona pellucida, plasma membrance and pronuclear envelope may be penetrated by an injection pipette. The blunt holding pipette may have a diameter of approximately 50 jum. The injection pipette may have a diameter of approximately 1.5 urn. The amount of gene construct injected will necessarily be dependent upon the size of the pronucleus and the size of the injection pipette. For example, a few hundred copies of a 2.6 kilobase (kb) linea fragment containing the desired gene characteristic hormone may be injected. The egg may be subsequently implanted by any suitable method into any suitably prepared surrogate mother. This may be achieved by any known method. To further illustrate the invention the following non-limiting example is provided: EXAMPLE 1 PGH cDNA sequences A porcine pituitary cDNA library of approximately 4000 individual recombinants constructed using the plasmid vector pUC19 (Norrander et al., Gene, 26, 101-106 1983) allowed the isolation of PGH cDNA clones using a synthetic DNA probe. One of the cDNA clones isolated, pPG.3, which was found to contain an insert of the expected full length, was completely sequenced. The open reading frame of the pPG.3 cDNA insert was found to code for a 216 amino acid pre-hormone, identical in amino acid sequence to the partial length PGH cDNA clone of Seeburg et al. DNA, 2, 37-45 (1983). This clone provided for the first time the complete sequence of the region encoding the PGH signal sequence and 41 basis of the 5' untranslated region. The nucleotide sequence within the coding region is very highly conserved, with only a single base difference from the sequence of Seeburg et al (1983). Figure 3 Nucleotide sequence of the PGH σenomic σene The complete 2231 bp sequence is illustrated. The open reading frame which enclodes pre-PGH is indicated, as are basis which differ in sequence from the previously studied PGH cDNA sequence,pPG.3. Base changes which result in animo acid substitutions are marked with an asterisk. The single base in the 3' untranslated region which differs from pPG.3 is also indicated below the sequence. The location of the cap site (+1) was inferred from the position of the rat and human GH gene cap sites (Page 35 al., 1981; DeNoto et al., 1981). Putative promoter and polyadenylation sequence, such as the TATA, AATAAA and GT-rich sequences are underlined, and the position at which the poly A tail is added is indicated with an arrow. The variant GC donor splice site is located in the first intron, around base +72. The Smal restriction site utilized for subcloning in latter Chapters is indicated. Southern analysis using a PGH cDNA hybridization probe When the cDNA insert of pPG.3 was used to probe Southern blots of porcine genomic DNA digested with three different restriction enzymes, a single strongly hybridizing band was detected in each track. Enzymes BamHI and EcoRI also produced a second,, fainter band, indicating that if the gene was in fact present as a single copy, the genomic gene must contain internal sites for both of these enzymes, somewhere near the end of the region homologous to the cDNA (as was later discovered to be correct). The third enzyme used, Hind III, produced only a single clear band. . Taken together these data indicated that only a single copy of the GH gene exists in the porcine genome (per hapoid chromosome comlement) , a situation analogous to the bovine and rat genomes, but very different to that of humans. Isolation and analysis of the genomic PGH gene The PGH cDNA clone pPG.3 was used to screen a porcine cosmid library and isolate a clone containing PGH gene sequences (2.4). Southern analysis of the cosmid clone identified major BamHI and EcoRI hybridizing bands where were equal in size to those detected in genomic Southerns utilizing the same hybridization probe. Nucleotide sequencing of the gene contained within the cosmid revealed that the entire coding region was present (648 bp) , along with 178 bp of the promoter region, 61 bp of 5' untranslated sequence, four introns of 242, 210, 197 and 278 bp respectively, and 414 bp of 3 ' non-coding sequence (Figure 3). The gene contains four base alterations within the coding region relative to the previously sequenced PGH cDNA clone, pPG.3. The base substitutions, which are illustrated in Figure 3, result in the alteration of two amino acid residues within the signal peptide. The remaining two differences are silent substitutions. There is also one base change in the 3* untranslated region relative to the pPG.3 cDNA sequence (Figure 3). The sequence comparison illustrated in Figure 4 indicates that the promoters of each of the studied sequences share a high degree of homology. Figure 3 indicates that the 5' untranslated regions of the GH and HPL genes are also conserved to a surprising degree. Analysis of the 3' sequences of the PGH gene allowed the identification of sequences which have been shown to be important in the polyadenylation process. The comparison of the 3 ' sequences of the PGH gene to all of the available GH and HPL squences has revealed that these are also conserved to a surprising extent, between both GH and HPL genes. Figure 4 Comparison of GH and HPL gene promoter and 5' untranslated sequences Porcine (P) , bovine (B) , human (H) and rat (R) GH genes and the human placental lactogen (HPL) gene were aligned to determine the extent of sequence homology (2.5.3). Asterisks indicate homology between adjacent sequences. The PGH sequence is numbered with respect to the distance from the cap site (+1) . This example describes the cloning of the porcine GH cDNA insert contained in pPG.3 into a bacterial expression vector. Expression of PGH in E.coli The expression vector chosen for the production of PGH in E.coli cells was pKT52. This plasmid, kindly provided by J. Shine (California Biotechnology), is a small, high copy number expression vector which contains a powerful, regulatable trc promoter (Brosius et al., 1985) and the strong E.coli 5S transcription terminators (Brosius et al, 1981) . The trc promoter is a fusion promoter containing the consensus -35 region of the E.coli trp promoter moined to the consensus -10 region of the E.coli lacUV5 promoter (do Boer et al., 1983a). The lacUV5 sequences of this promoter contain a lac operator site, which results in transcription from this promoter being repressed in lacl q strains. Transcription from this promoter in lac I q strains can be stimulated by growing cells in the presence of IPTG (de Boer et al., 1983a). A restriction map and the sequence of the RBS/ cloning region of pKT52 is shown in Figure 5. Figure 5 Cloning PGH cDNA into expression vector pKT52 The organization of the E.coli expression vector pKT52 is illustrated. An 800 bp Pstl fragment was isolated from M13 RF containing the EcoRI insert of pPG.3. This fragment contained the entire pre-PGH coding region, minus the first two amino acids, plus 33 bp of mpl9 polylinker DNA. When this fragment was inserted into the Pstl site of pKT52, the full pre-PGH sequence is regenerated (3.2.1). The EcoRI insert of pKT52 was then isolated and cloned into M13 mpl9 to facilitate mutagenesis of the pKT52/PGH cDNA junction point (3.2.2). The position of the trc promoter and the 5S rRNA transcription terminators (rrnTl and rrnT2) are indicated. Two E.coli strains were used for analysing expression levels in the work described in this Example, strains MC1061 and JM101. Expression from the trc promoter is constitutive inMC1061 cells, and repressed in the lac I q strain, JM101. The repression of transcription from the trc promoter in JM101 cells was released by growing cells in the presence of 1 mM IPTG. Plasmid pGHX.l A construct designed to express methionyl-PGH (m-PGH) was constructed using oligonucleotide directed mutagenesis to delete the DNA coding for amino acids 2-26 of the pre-hormone. This deletion joined the TTc codon of the first amino acid of the mature PGH molecule directly to the ATG initiator codon. The EcoRI insert of pKTGH, which contains the entire PGH cDNA fused to the trc promoter sequences, was isolated and cloned into M13 m l9. Single-stranded DNA isolated from this 'phage was then used in mutagenesis reactions. To remove the 75 bases coding for amino acids 2-26 of the pre-hormone a 30 base long oligonucleotide, GH.30, complementary to 15 basis either side of the required deletion was used in a mutagenesis reaction. Following annealing and extension the mutagenesisreaction was transformed into JM101. The resulting plaques were then screened to detect the required deletion by plaque hybridization of dupliate lifts made from the transformation plates. Of the 150 plaques screened 35% were found to hybridize in duplicate to the GH.30 oligonucleotide probe. Single-stranded DNA was isolated from a number of positive plaques and sequenced to confirm the accuracy of the deletion using the PGH-specific oligonucleotide, GH.25, as primer. All of the positive plaques contained DNA which had the correct deletion. Replicative form (RF) DNA was isolated from this deleted 'phage (mpGHX.l) and the EcoRI insert purified and subcloned into the larger EcoRI fragment of pKTGH to create plasmid pGHX.l. The nucleotide sequence of the 5' end of this, and the other expression plasmids described are illustrated in Figure 6. Figure 6 Nucleotide sequence of 5' regions of PGH expression plasmids The nucleotide sequence of the final 24 basis of the mRNA leader and the 5' end of the coding region of each of the expression plasmids generated in Chapter 3 are illustrated. Each of the sequences were determined by priming sequencing reactions with the PGH specific oligonucleotide, GH.25 (Figure 5; 6.2.5). Each of the plasmids with the exception of pKTGH (pre-PGH) and pGHXF (PGH fusion protein) encode methionyl-pGH ( -PGH) . Bases of the m-PGH expression plasmids which differ from the pGHX.l sequence have been underlined. pGHXS (spacer) plasmids A 38 base oligonucleotide with one redudnancy, GH.38, was designed to alter the RBS from AGGAAA to AGGAGG and the spacer from CAGACC to either TAATAT or TAAAAT. Single-stranded DNA containing the small EcoRI fragment of pGHX.l was mutagenized and positive plaques selected and sequenced. A total of 30% of the plaques hybridized to the GH.38 probe, but of these only 20% contained either the GGTAATAT or GGTAAAAT RBS/spacer sequences. The remaining positives contained duplicate insertions which may have arisen due to the incorrect hybridization of the GH.38 oligonucleotide during the mutagenesis reaction. RF DNA was prepared from plaques containing correct versions of both the required alterations and then cloned back into pKTGH. The nucleotide sequence of the RBS/spacer region of the resulting plasmids, pGHXS.4 and pGHXS.9 are illustrated in Figure 4. Extracts prepared from both MC1061 and induced JM101 cells containing either of these two plasmids were found to contain an additional prominent band, which had a molecular weight of 22 K, the expected size of m-PGH. Laser densitometry of SDS/PAGE gels indicated that both plasmids produced identical levels of m-PGH, which ranged in the two hosts from 15 to 20% of total cellular protein. Figure 7 illustrates the level of m-PGH produced from pGHXS.4 in both uninduced and induced JM101 cells. This Figure also illustrates the similarity in molecular weight of the E.coli produced protein versus pituitary derived PGH. The m-PGH migrates at a slightly higher molecular weight than expected (approximately 200 daltons), probably due to the extremely crude nature of the protein extracts applied to the gel. This phenomenon has been previously observed in crude bacterial extracts containing human GH (Hsiung et al., 1986). Figure 7 Production of m-PGH by plasmid pGHXS.4 Protein extracts from uninduced (-IPTG) and induced (+IPTG) JM101 cells containing expression plasmid pGHXS.4 were subjected to SDS/PAGE, along with molecular weight markets and purified, pituitary derived PGH (kindly provided by R. Seamark) . A prominent band of the expected molecular weight of PGH (22,000 daltons) is produced only in IPTG induced cells (3.2.2.iii). The construction of a human MT-IIA promoter/PGH fusion gene The promoter chosen for these studies was the human metallothioneine II-A promoter (Karin and Richards, 1982) which was kindly provided by R. Richards. The hMT-IIA promoter was available as an 823 bp fragment with promoter sequences extending from -763 to +60 cloned in the M13 vector mp8 (A. Robbins pers. comm.). The double digestion of RF "phage containing this promoter with Hindlll and EcoRI releases the promoter sequences fused to 5 bp of vector polylinker sequence. This 823 bp fragment was purified and subcloned into Hindlll/EcoRI digested pUC19 to generate plasmid pUCMT. The sequences encoding PGH were isolated from the PGH cDNA clone pPG.3 as an 814 bp EcoRI fragment. This ws cloned downstream of the hMT-IIA promoter, by restricting pUCMT with EcδRI, followed by ligation to the puriied pPG.3 insert. Restriction analysis of plasmid DNA prepared from the resulting transformants (6.3.4.ii) identified a plasmid which contained the PGH cDNA inserted in the correct orientation, which was named pUCMTGH.4 (Figure 6). The nucleotide sequence of the junction point between these two fragments was determined by the directional subcloning of a restriction fragment spanning this region into M13 mpl8. The sequence data derived from this clone indicated that the expected sequence had been generated, and had contained the hMT-IIA promoter sequences and transcription start site (down to position +60) joined to the PGH 5' untranslated region (from +21 onwards) by 9 bp of polylinker/synthetic linker DNA (Figure 8) . It was decided to subclone the 1 kb Smal/BamHI fragment from plasmid pGHB.3 (2 kb BamHI subclone of cPGH.l) which contains the fif h exon downstream of the Sma I site plus approximately 800 bp of 3' non-translated sequence from the pgh gene into the unique SmaI site of pUCMTGH.4. The 1 kb Smal/BamHI fragment of pGHB.3. was purified (6.3.2.U) and the BamHI generated overhang repaired with the Klenow fragment of E.coli DNA polymerase I. This blunt-ended fragment was then subcloned into Smal digested pUCMTGH.4. The examination of plasmid DNA isolated from a number of the resulting transformants revealed that most were equal in size to pUCMTGH.4. The transformants were therefore screened for the presence of the cPGH.l sequences by filter hybridization using a 500 bp Baml/Pstl restriction fragment from the far 3' end of pGHB.3 as the hybridization probe. Restriction analysis of plasmid DNA prepared from the resulting positives indicated that one contained the inserted fragment in the correct orientation. This plasmid was named pHMPH.4 (HM, human metallothionein; PG, porcine growth hormone) . The organization of this plasmid is illustrated in Figure 1. Figure 2 Construction of eukarvotic expression plasmid pHMPG.4 A flow chart illustrating the construction of pHMPG.4 is illustrated. An approximate 800 bp Hindlll/EcoRI fragment containing the hMT-IIA promoter was cloned into Hindlll/EcoRi digested, dephosphorylated pUC19 to create plasmid pUCMT. This plasmid was then restricted with EcoRI, dephosphorylated, and ligated to the EcoRI insert of the PGH cDNA clone, pPG.3, to generate plasmid pUCMTGH.4. This plasmid was restricted with Smal, dephosphorylated, and ligated to the blunt-ended 1 kb Smal/BamHI insert of cosmid subclone pGHB.3, which contains most of the last exon of the PGH genomic gene and approximately 700 bp of PGH 3 ' non-coding sequence to create pHMG 4. All constructs were checked by DNA sequence analysis.. Figure 8 Nucleotide sequence of the hMT-IIA/PGH junction point in pUCMTGH.4 A Scal/Pstl fragment which covers the junction region between hMT-IIA and PGH cDNA sequences was isolated from pUCMTGH.4 and cloned into Smal/Pstl digested mpl8 for sequence analysis. The sequence data from this clone indicated that the correct fusion had been generated, with the hMT-IIA promoter, cap site (there are two cap sites, both indicated as +1), and 5' untranslated sequences (extending down to +60), linked 'to the PGH cDNA sequences,. which extend downstream from base +21, by 9 bp of synthetic linker sequence (4.2) . Figure 1 Expression vector, pHMPG.4 The restriction map and organization of expression vector pHMPG.4 is illustrated. The hMT-IIA promoter sequences are fused to a hybrid gene containing PGH cDNA sequences extending from +21 down to the unique Smal site, joined to PGH genomic gene sequences downstream from this point. The 2.7 kb Hindlll/Pvul fragment containing all of the promoter and PGH sequences, plus 120 bp of the pUC19 lacz gene joined to the 3' end, was purified from low meltong temperature agarose, and used for generating transgenic animals. Production of transgenic pigs The Hindlll/Pvul fragment of pHMPG.4 was used to produce transgenic pigs. Single cell in vivo fertilized pig embryos were collected from superovulated large white sows. These were prepared and injected with approximately 600 copies of the pHMPG.4 insert. Approximately 30 injected embryos were surgically transferred into the oviducts of each of a number of synchronized recipient sows. Four of these sows farrowed small litters (4-5 per litter) , producing a total of 17 piglets. Analysis of transgenic pigs i) Dot-blots The piglets were tested for the presence of the foreign gene by dot-blot hybridization of DNA isolated from tail tissue. Both normal pig DNA and human genomic DNA were included on these dot-blots to act as negative and positive controls respectively. Following the hybridization of these dot-blots to the Hindlll/Aval fragment of the hMT-IIA promoter a number of positive signals were evident. Four of the pigs showed strong hybridization equivalent to greater than one copy per cell and a further two showed weak hybridization, slightly above background, and equivalent to less than one copy per cell (Figure 9). ii) Slot-blots The number of copies per cell of the pHMPG.4 insert present in each of the transgenic pigs was determined by slot-blot analysis. Five ug samples of tail DNA from each of the transgenic animals was filtered onto a slot-blot along with human and pig positive and negaitve controls. A range of amounts of pHMPG.4 plasmid DNA (which also contained 5 μg of control pig genomic DNA) corresponding to genomic copy numbers equivalent to between one and fourty copies per cell were also included. This slot-blot was hybridized to the nick-translated Hindlll/Aval fragment of the hMT-IIA promoter and washed at high stringency. The intensity of hybridization of the transgenic animals was compared to the plasmid standard s by laser densitometry, and found to range from approximately 0.5 copies per cell in animals #375 and #739 to 15 copies per cell in animal #295 (Table 1; Figure 9). iii) Southern Analysis The organization of the foreign sequences within the transgenic pigs was studied by Southern blotting. There are no BamHI sites within the pHMPG.4 insert. The digestion of the genomic DNA of the transgenic animals with this enzyme should therefore produce bands on genomic Southerns, the length of which are governed by the distance of the nearest BamHI sites to the site of integration, the number of integration sites, and the number of integrated copies of the pHMPG.4 insert. Figure 9 Analysis of potentially transgenic pigs by dot.-blot 10, 5, and 1 μg samples of DNA isolated from the tails of pigs which had developed from eggs microinjected with the insert of pHMPG.4, were denatured and applied to a membrane. pHMPG.4 and human (HUM) genomic DNA positive controls and pig (PIG) genomic DNA negative controls were included on each dot-blot array. The plasmid positive controls are in row 1, blot A. In this row the numbers in brackets refer to the number of copies per cell each plasmid dot is equivalent to. Samples in rows A4 to All and Bl to B9 contain the test pig samples. The nick-translated hMT-IIA promoter Hinlll/Aval insert ws used as the hybridization probe. A key indicating the identity of the sample on each dot is shown below. 8 10 11 A. 10μg (2) HUM PIG 177 178 179 180 295 296 297 298 B. 5μg (1) C. lμg (0.5) " B. 8 10 11 A. lOμg 373 374 375 376 735 736 737 738 739 PIG HUM B. 5μg (1) C. lμg (0.5) " Figure 10 Slot-blot analysis of transgenic pigs Samples (5 ^ μg) of transgenic pig DNA and pig (PIG) and human (HUM) negative and positive controls were denatured and applied to a membrane along with a number of samples containing various amounts of pHMPG.4 plasmid DNA combined with 5 μg of pig control DNA. The amounts of pHMPG.4 DNA applied correspond to gene copy numbers of between 1 and 40 gene copies per cell (shown in brackets below) . The probe used was the nick-translated hMT-IIA promoter Hindlll/Aval insert. A key to the samples on the blot is given below. Quantitation of the intensity of hybridization of each of the samples on this membrane was performed using a laser densitometer. The results of this analysis are presented in Table below. B 1. 177 180 295 2. 375 736 739 3. PIG HUM 4. 5. 500 (40) 125 (10) 50 (4) 6. 375 (30) 100 (8) 25 (2) 7. 250 (20) 75 (6) 12.5 (1) Table 1 Transgenic pigs: gene copy number, growth, and serum PGH concentration The number of copies (per cell) of the foreign gene present in each of the transgenic pigs estimated by slot-blot analysis, the daily weight gain (between days 50 and 120) and the serum PGH concentration of each of the transgenic pigs and their non-transgenic littermates are illustrated. The female control values are the mean of three animals, and the male control values are the mean of two animals. Pig No. sex copy no./ daily weight serum PGH cell gain (am) cone . (ng/ml) 177 F 3 765 10.4 295 F 15 953 27.8 739 F 0.5 686 6.9 controls F - 806 10.6 180 M 6 851 15.3 375 M 0.5 487 6.3 736 M 6 857 11.1 controls M _ 670 15.3 Figure 11 Growth rate of transgenic pigs The growth performance of each of the transgenic pigs is plitted against the growth rate of non-transgenic littermates. The dotted lines represent the average growth rate of sex-matched non-transgenic littermates, the dashed line represents the average of non-transgenic littermates of the opposite sex, and solid lines represent transgenic animals. Example 2 Spl binding site minus hMT-IIA/PGH plasmid, pHMGPG.3 It has been reported that a consensus Spl binding site sequence, GGGCGG (Kadonaga et al., Trends Biochem. Sci. 11, 20-23, 1986) located adjacent to the basal level sequence, would generate a promoter with the desired parameters. The nucleotide sequence of an altered hMT-IIA promoter which has the Spl binding site replaced with a Pstl linker, and possesses the required transcriptional characteristics, was kindly made available by M. Karin. This alteration was recreated in the hMT-IIA/ mp8 clone by oligonucleotide directed mutagenesis. A 46 base long oligonucleotide, MT.46 was designed to replace a 15 bp region, surrounding and including the Spl binding site, with a 17 base long Pstl linker sequence. Following mutagenesis of hMT-IIA/ mp8 single-stranded DNA with MT.46 and transformation into JM101 plaques containing the correct squence substitution were selected by plaque hybridization and nucleotide sequencing. RF DNA was isolated from one of the plaques containing the correct mutation and the Hinlll/EcoRI insert purified and used in a triple ligation with the EcoRI insert of pHMPG.4 and Hindlll/EcRI digested pUC19 DNA. One of the resulting plasmids from this ligation contained the correct restriction pattern, and was named pHMGPG.3 (GC sequence minus). The insert of this plasmid is currently being introduced into transgenic mice. It is also envisaged that the process of the present invention may be used to produce synthetic promoter constructs containing various combinations of metal-responsive elements corresponding to sequences found in mouse, sheep or human metallothioneine promoters, with or without other promoter elements. For example it may be used to regulate Fe levels. Finally, it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention as outlined herein.

Claims: CLAIMS : 1. A method for creating new breeds of animals which comprises: (a) obtaining a recently fertilised ovum; (b) isolating a gene sample of a characterising hormone homologous with the ovum; (c) introducing the gene sample into the male nucleus of the ovum prior to fusion with the female nucleus to form a single cell embryo; and (d) subsequently implanting the ovum into a suitably prepared female animal. 2. A method according to Claim 1 wherein the animal is selected from horses, cows, pigs, sheep, goats, turkeys and marine animals. 3. A method according to Claim 2 wherein the characterising hormone is a porcine growth hormone. 4. A method according to Claim 3 wherein the animal is a pig. 5. A plasmid expression vector comprising a plasmid cloning vector including a first cloned sequence of DNA encoding a non-porcine promoter region and a second cloned sequence encoding porcine growth hormone activity. 6. A plasmid expression vector according to Claim 5 wherein the plasmid cloning vector is selected from pUC19 or pKT52. 7. A plasmid expression vector according to Claim 5 or Claim 6 wherein the first cloned sequence of DNA encodes human metallothioneine promoter (hMTIIA) . 8. A plasmid expression vector according to any one of Claims 5 to 7 wherein the first cloned sequence of DNA forms an EcoRI-Hindlll insertion in the plasmid cloning vector and is of approximately 810-823bp in length. 9. A plasmid expression vector according to any one of Claims 5 to 8 wherein the second cloned sequence forms an EcoRI-EcoRI insertion in the plasmid cloning vector and is of approximately 522bp in length. 10. A plasmid expression vector according to any one of Claims 5 to 9 which includes a third cloned sequence of DNA inserted in the second cloned sequence. 11. A plasmid expression vector according to Claim 10 wherein the third cloned sequence comprises the 3 ' end of the porcine growth hormone gene. 12. A plasmid expression vector according to Claim 10 wherein the third cloned sequence forms an Sma:Bam/Sma insertion in the second cloned sequence of approximately lOOObp in length. 13. A plasmid expression vector according to Claim 10 or Claim 11 wherein the 3' end is modified by deleting regions identified as repeating sequences. 14. A plasmid expression vector according to Claim 5 comprising pHMPG.4. 15. A method of preparing a plasmid expression vector as defined by any one of Claims 5 to 14 comprising: - providing a suitable plasmid cloning vector, a first fragment of DNA containing a non-porcine promoter, and a second fragment of DNA coding for porcine growth hormone; - inserting the first fragment of DNA into the plasmid cloning vector at a suitable site; and - inserting the second fragment of DNA into the plasmid cloning vector at a suitable site. 16. A method of preparing a transgenic animal which includes: (a) providing a recently fertilised ovum from a female of the animal, (b) preparing a plasmid expression vector as defined by any one of Claims 5 to 14, (c) injecting the plasmid into the male pronucleus prior to fusion with the female nucleus to form a single cell embryo, and (d) subsequently implanting the ovum into a suitably prepared female animal. 17. A method according to Claim 16 wherein the animal is a pig.

Inventors: SEAMARK ROBERT FREDERICK, WELLS JULIAN RICHARD ESTE, SEAMARK, ROBERT, FREDERICK, WELLS, JULIAN, RICHARD, ESTE
Applicants: LUMINIS PTY LTD
Application year: 1988
Main classification: C12N15
IPC codes: A01K61, A01K67, C07K14, C12N5, C12N15